Evaxion announces positive preclinical data for cytomegalovirus (cmv) vaccine program evx-v1

Copenhagen, denmark, november 12, 2024 - evaxion biotech a/s (nasdaq: evax) (“evaxion”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, announces new positive preclinical data from its ongoing cytomegalovirus (cmv) vaccine program named evx-v1. the data will be presented today at the 9th international conference on vaccines research & development, taking place in boston, usa.
EVAX Ratings Summary
EVAX Quant Ranking